{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T03:04:42Z","timestamp":1789873482298,"version":"4.0.1"},"reference-count":19,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T00:00:00Z","timestamp":1735344000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.japh.2024.102318","type":"journal-article","created":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T16:25:40Z","timestamp":1735316740000},"page":"102318","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparative effectiveness of buprenorphine adherence with telemedicine vs. in-person for rural and urban patients"],"prefix":"10.1016","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1081-1670","authenticated-orcid":false,"given":"Thomas J.","family":"Reese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8407-7333","authenticated-orcid":false,"given":"Nana Addo","family":"Padi-Adjirackor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin N.","family":"Griffith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2066-8692","authenticated-orcid":false,"given":"Bryan","family":"Steitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen W.","family":"Patrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley A.","family":"Leech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0699-4224","authenticated-orcid":false,"given":"Andrew D.","family":"Wiese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6844-145X","authenticated-orcid":false,"given":"Adam","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0930-561X","authenticated-orcid":false,"given":"Mauli V.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3859-9130","authenticated-orcid":false,"given":"Jessica S.","family":"Ancker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.japh.2024.102318_bib3","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/ajad.12805","article-title":"Expanding access to buprenorphine treatment in rural areas with the use of telemedicine","volume":"27","author":"Weintraub","year":"2018","journal-title":"Am J Addict"},{"key":"10.1016\/j.japh.2024.102318_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108492","article-title":"Comparing telemedicine to in-person buprenorphine treatment in U.S. veterans with opioid use disorder","volume":"133","author":"Lin","year":"2022","journal-title":"J\u00a0Subst Abuse Treat"},{"issue":"8","key":"10.1016\/j.japh.2024.102318_bib6","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.25999","article-title":"Buprenorphine prescribing characteristics following relaxation of X-waiver training requirements","volume":"7","author":"Christine","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.japh.2024.102318_bib7","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/ajad.13540","article-title":"Impact of inpatient addiction psychiatry consultation on opioid use disorder outcomes","volume":"33","author":"Kast","year":"2024","journal-title":"Am J Addict"},{"issue":"5","key":"10.1016\/j.japh.2024.102318_bib8","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1007\/s11606-022-07941-3","article-title":"Evaluation of compensatory prescribing after opioid-restricting legislation","volume":"38","author":"Reese","year":"2023","journal-title":"J\u00a0Gen Intern Med"},{"key":"10.1016\/j.japh.2024.102318_bib9","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1097\/00005650-198808000-00007","article-title":"A\u00a0general method of compliance assessment using centralized pharmacy records: description and validation","volume":"26","author":"Steiner","year":"1988","journal-title":"Med Care"},{"key":"10.1016\/j.japh.2024.102318_bib10","author":"Halekoh"},{"issue":"1","key":"10.1016\/j.japh.2024.102318_bib13","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1540-5907.2012.00602.x","article-title":"Behind the curve: clarifying the best approach to calculating predicted probabilities and marginal effects from limited dependent variable models","volume":"57","author":"Hanmer","year":"2013","journal-title":"Am J Polit Sci"},{"issue":"11","key":"10.1016\/j.japh.2024.102318_bib14","doi-asserted-by":"crossref","first-page":"867","DOI":"10.2471\/BLT.07.045120","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"85","author":"Von Elm","year":"2007","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.japh.2024.102318_bib15","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2147\/SAR.S150253","article-title":"Relationship between buprenorphine adherence and relapse, health care utilization and costs in privately and publicly insured patients with opioid use disorder","volume":"9","author":"Ronquest","year":"2018","journal-title":"Subst Abuse Rehabil"},{"issue":"4","key":"10.1016\/j.japh.2024.102318_bib16","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jsat.2013.10.014","article-title":"Relationship between buprenorphine adherence and health service utilization and costs among opioid dependent patients","volume":"46","author":"Tkacz","year":"2014","journal-title":"J\u00a0Subst Abuse Treat"},{"key":"10.1016\/j.japh.2024.102318_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108317","article-title":"Adherence to buprenorphine: an analysis of prescription drug monitoring program data","volume":"216","author":"Pizzicato","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.japh.2024.102318_bib18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jsat.2019.05.015","article-title":"A\u00a0comparison of adherence, outcomes, and costs among opioid use disorder Medicaid patients treated with buprenorphine and methadone: a view from the payer perspective","volume":"104","author":"Kinsky","year":"2019","journal-title":"J\u00a0Subst Abuse Treat"},{"issue":"2","key":"10.1016\/j.japh.2024.102318_bib19","first-page":"138","article-title":"Treatment outcome comparison between telepsychiatry and face-to-face buprenorphine medication-assisted treatment for opioid use disorder: a 2-year retrospective data analysis","volume":"11","author":"Zheng","year":"2017","journal-title":"J\u00a0Addict Med"},{"issue":"1","key":"10.1016\/j.japh.2024.102318_bib20","first-page":"E40","article-title":"A\u00a0telemedicine buprenorphine clinic to serve New York city: initial evaluation of the NYC public hospital system's initiative to expand treatment access during the COVID-19 pandemic","volume":"16","author":"Tofighi","year":"2022","journal-title":"J\u00a0Addict Med"},{"issue":"5","key":"10.1016\/j.japh.2024.102318_bib21","first-page":"540","article-title":"Provider perceptions toward extended-release buprenorphine for treatment of opioid use disorder","volume":"18","author":"Reddy","year":"2024","journal-title":"J\u00a0Addict Med"},{"issue":"12","key":"10.1016\/j.japh.2024.102318_bib22","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1093\/pm\/pnae061","article-title":"Tapering opioids in patients with persistent pain after cancer treatment","volume":"25","author":"Butler","year":"2024","journal-title":"Pain Med"},{"issue":"9","key":"10.1016\/j.japh.2024.102318_bib23","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1001\/jamainternmed.2023.2826","article-title":"Buprenorphine out-of-pocket costs and discontinuation in privately insured adults with opioid use disorder","volume":"183","author":"Leech","year":"2023","journal-title":"JAMA Intern Med"},{"issue":"3","key":"10.1016\/j.japh.2024.102318_bib24","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/00952990.2019.1694536","article-title":"A\u00a0systematic review of rural-specific barriers to medication treatment for opioid use disorder in the United States","volume":"46","author":"Lister","year":"2020","journal-title":"Am J Drug Alcohol Abuse"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319124003492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319124003492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:38:48Z","timestamp":1741653528000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319124003492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1544319124003492"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2024.102318","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative effectiveness of buprenorphine adherence with telemedicine vs. in-person for rural and urban patients","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2024.102318","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Pharmacists Association\u00ae. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102318"}}